FDA Approval Insights: Isatuximab Plus Carfilzomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Season 5 Episode 31  ·  Aug 09, 2021, 06:49 PM

Headliner
Share
Subscribe

Dr. Moreau discusses the FDA approval of isatuximab-irfc plus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma, key findings from the pivotal IKEMA trial, and future directions with the combination.

Share
Subscribe
Next
Making the Most of Molecular Testing in Breast Cancer
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air